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Abstract
Aims/hypothesis Weight-loss programmes for adults with type 2 diabetes are less effective in the long term owing to regain of
weight. Our aim was to determine the 2 year effectiveness of a cognitive behavioural group therapy (group-CBT) programme in
weight maintenance after diet-induced weight loss in overweight and obese adults with type 2 diabetes, using a randomised,
parallel, non-blinded, pragmatic study design.
Methods We included 158 obese adults (median BMI 36.3 [IQR 32.5–40.0] kg/m2) with type 2 diabetes from the outpatient
diabetes clinic of Erasmus MC, the Netherlands, who achieved ≥5% weight loss on an 8 week very low calorie diet. Participants
were randomised (stratified by weight loss) to usual care or usual care plus group-CBT (17 group sessions). The primary
outcomes were the between-group differences after 2 years in: (1) body weight; and (2) weight regain. Secondary outcomes
were HbA1c levels, insulin dose, plasma lipid levels, depression, anxiety, self-esteem, quality of life, fatigue, physical activity,
eating disorders and related cognitions. Data were analysed using linear mixed modelling.
Results During the initial 8 week dieting phase, the control group (n = 75) lost a mean of 10.0 (95% CI 9.1, 10.9) kg and the
intervention group (n = 83) lost 9.2 (95%CI 8.4, 10.0) kg (p = 0.206 for the between-group difference). During 2 years of follow-
up, meanweight regain was 4.7 (95%CI 3.0, 6.3) kg for the control group and 4.0 (95%CI 2.3, 5.6) kg for the intervention group,
with a between-group difference of −0.7 (95%CI −3.1, 1.6) kg (p = 0.6). The mean difference in body weight at 2 years was −1.2
(95% CI −7.7, 5.3) kg (p = 0.7). None of the secondary outcomes differed between the two groups.
Conclusions/interpretation Despite increased treatment contact, a group-CBT programme for long-term weight maintenance
after an initial ≥5% weight loss from dieting in obese individuals with type 2 diabetes was not superior to usual care alone.
Trial registration Trialregister.nl NTR2264
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Introduction
Lifestyle interventions that reduce weight improve a number
of cardiovascular disease risk factors in adults with type 2
diabetes [1, 2], but studies using hard endpoints have been
disappointing. In the Look Action for Health in Diabetes
(AHEAD) trial, an intensive lifestyle intervention led to a
number of beneficial effects on health and quality of life, but
not on cardiovascular outcomes [3]. Weight regain during
follow-up in a substantial proportion of the participants may
have contributed to this unexpected outcome [4, 5].
Obviously, non-invasive weight-loss interventions require
strategies that prevent regain of body weight to achieve clin-
ically relevant effects.
Cognitive behavioural therapy (CBT) in general, and cog-
nitive behavioural group therapy (group-CBT) in particular,
has been shown to be effective in weight management and
weight-loss maintenance after dieting in obese adults without
type 2 diabetes [6–9]. While standard behavioural therapy
focuses on techniques to change behaviour directly (e.g.
self-monitoring, goal setting), CBT aims to change dysfunc-
tional thoughts about self-image and behaviour into more re-
alistic, helpful thoughts that may facilitate long-term behav-
ioural change. Obese people with type 2 diabetes differ from
the ‘healthy’ obese in many ways: they have more metabolic
problems, greater use of medication, higher prevalence of co-
morbidities, and lower quality of life, all of which may poten-
tially affect an individual’s ability to lose or maintain weight.
In obese individuals with type 2 diabetes, lifestyle interven-
tions using standard behavioural therapy have shown only a
moderate effect on weight loss [10], while the two observa-
tional studies published to date on the effect of group-CBT as
part of weight-loss programmes have shown more favourable
effects on weight loss [11, 12]. However, the effect of group-
CBT on weight-loss maintenance has not been investigated in
individuals with type 2 diabetes.
The primary objective of this study was to determine the
2-year effectiveness of a group-CBT programme on top of
usual care in weight maintenance after diet-induced weight
loss in overweight and obese adults with type 2 diabetes, using
a pragmatic study design. Secondary objectives were to eval-
uate the effects of group-CBT on cardiovascular risk factors
and psychological wellbeing.
Methods
Study design The protocol of the ‘Prevention of Weight
Regain’ (POWER) trial has been published previously [13].
The POWER study was a parallel-group, randomised con-
trolled trial that was conducted between March 2010 and
May 2015. The study was approved by the medical ethics
commit tee of the Erasmus MC (MEC-2009-143/
NL26508.078.09) in compliance with the Helsinki
Declaration of 2008. All participants provided written in-
formed consent.
Study population Overweight and obese (BMI >27 kg/m2)
adults with type 2 diabetes and aged 18–75 years were recruit-
ed from the outpatient diabetes clinic of Erasmus MC. This
hospital is a tertiary referral centre, but individuals with severe
comorbidities were excluded from this trial. Some of the par-
ticipants were referred by their general practitioners specifi-
cally for participation in this trial. Exclusion criteria were:
•
•
•
•
•
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pregnancy; lactation; inadequate understanding of the Dutch
language; severe psychiatric problems; significant cardiac ar-
rhythmias; unstable angina; decompensated congestive heart
failure; carcinomas; major organ system failure; untreated hy-
pothyroidism; end-stage renal disease; and myocardial infarc-
tion, cerebrovascular accident or major surgery during the
previous 3 months. We recorded the age, sex and ethnicity
of individuals who met the eligibility criteria but declined to
participate.
Weight-loss dieting After collection of baseline data, partici-
pants started with a diet very low in energy (very low calorie
diet; VLCD) of approximately 3140 kJ (750 kcal)/day for
8 weeks. Blocks of 20 participants started with the diet con-
comitantly. The daily diet consisted of two diabetes-specific
meal replacements (Glucerna, Abbott Nutrition, Columbus,
OH, USA) plus 75 g lean meat, 150 ml skimmed milk and
low-carbohydrate vegetables ad libitum. To reduce the risk of
hypoglycaemia, doses of sulfonylurea derivatives and insulin
were reduced at the start of the dietary intervention.
After 8 weeks the diet was changed into a low-energy diet
of 4600–5400 kJ (1100–1300 kcal)/day, gradually increasing
the intake during the following 12 weeks. From then on, the
participants ate a diet based on national health recommenda-
tions, aiming at weight maintenance. During the entire study,
60 min of moderately intensive exercise each day was recom-
mended, and glucose-lowering medication and insulin doses
were adjusted by the responsible physician based on plasma
glucose levels. Other medications remained unchanged.
Randomisation and masking After 8 weeks of the VLCD,
participants who had lost ≥5% of their body weight were
randomly assigned to either the control group or the interven-
tion group with an allocation ratio of 1:1. The block
randomisation was stratified by weight loss, with categories
5–7.5%, 7.5–10% and >10%. The participants, CBT thera-
pists and primary researcher (K. Berk) were not blinded to
the intervention, whereas the medical team at the outpatient
clinic was. Participants were not allowed to talk to their med-
ical team about the group-CBT sessions. The treatment of
diabetes and its complications (according to national guide-
lines) was not influenced by the allocation of the participants.
Blinded medical assistants took measurements (i.e. weight,
waist circumference, blood pressure) and all statistical analy-
ses were independently conducted by two researchers.
Control group: usual care The control group received the usu-
al care for diabetes regulation and cardiovascular risk man-
agement at our tertiary medical referral centre. This consisted
of scheduled visits every 3–6 months (sometimes on separate
occasions) to the internist and diabetes nurse, plus referral to a
dietitian or psychologist when indicated. In addition, during
the diet period participants using insulin frequently contacted
the diabetes nurse by email or telephone to optimally adjust
their insulin dose according to their glucose levels. The in-
creased attention (during additional visits) given to the inter-
vention group was not compensated for in the control group.
Intervention group: usual care plus group-CBT After
randomisation, participants allocated to the intervention group
started group-CBT with up to ten participants per group. The
first ten weekly sessions were followed by two fortnightly
sessions, two monthly sessions and two 3-monthly sessions,
with the last session taking place 18 months after
randomisation. The group-CBT sessions were conducted by
a trained psychologist/psychotherapist (H. Buijks or A. van ’t
Spijker) experienced in CBT as well as in diabetes care.
The protocol of the first ten group-CBTsessions was based
on the cognitive therapy described byWerrij et al [7]. The aim
of the first ten sessions, including one partner session, was to
restructure dysfunctional cognitions on lifestyle, weight and
body perception. The last seven sessions were devoted to
challenging dysfunctional cognitions of relapse. Only when
participants had fully mastered the cognitive behavioural tech-
niques were proactive coping and problem-solving techniques
[14–16] explained. A detailed description of the intervention
has been published previously [13]. Group-CBTwas given in
addition to usual care.
Outcome measures All primary and secondary outcome var-
iables were prespecified and are described inmore detail in the
study protocol [13]. Outcome variables were assessed at base-
line, at randomisation after 8 weeks of VLCD (primary out-
come only), at 12weeks (after the weekly group-CBTsessions
had finished) and at 52, 78 and 104 weeks after
randomisation.
The primary endpoints were the difference between the
study groups in body weight (kg) after 2 years of follow-up
and in weight regain (kg) from randomisation to 2 years.
Weight was measured to the nearest 0.1 kg after removal of
shoes, using a Seca 888 compact digital flat scale (Seca,
Hamburg, Germany).
Secondary outcomes (all defined as between-group differ-
ences) were as follows: change in weight (kg) from baseline to
2 years of follow-up; 2 year estimates and change from base-
line to 2 years in waist circumference (cm); systolic blood
pressure (mmHg); total cholesterol (mmol/l), LDL-
cholesterol (mmol/l), HDL-cholesterol (mmol/l), triacylglyc-
erol (mmol/l) and HbA1c (% and mmol/mol), all measured via
routine laboratory techniques; insulin dose (U/day); depres-
sion and anxiety (Hospital Anxiety and Depression Scale
[HADS] [17, 18]); self-esteem (Rosenberg Self-Esteem
Scale [19]); quality of life (EuroQol five-dimension question-
naire [20, 21]); fatigue (Checklist Individual Strength [22,
23]); physical activity (Short Questionnaire to Assess Health
Enhancing Physical Activity [24]); and eating disorders
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(Eating Disorder Examination Questionnaire [EDE-Q] [25])
and related cognitions (EDE-Q subscores of eating restraint,
eating concern, weight concern and shape concern; score
range 0–6). In addition to the predefined outcome variables,
we recorded the number of visits to physicians and paramedics
at the diabetes outpatient clinic. We counted visits to each
specialist separately, even when they occurred on the same
day. We also counted contacts by email or phone (as 0.333
of a visit). We managed our data using the trial management
system OpenClinica (Waltham, MA, USA).
Sample size To base the sample-size calculation on realistic 8-
week weight-loss data, an independent statistician carried out
a blinded power calculation after the first 75 participants had
completed the 8-week VLCD period, as described in the pro-
tocol [13]. Sample size was calculated with SPSS version 21.0
(www-01.ibm.com/support/docview.wss?uid=swg21608060)
using the mixed-model ANOVA procedure described by
Aberson [26]. Alpha was set at 0.05, power at 0.80 and the
baseline–end correlation at 0.90. A clinically relevant differ-
ence between the treatment groups was set at 5% weight loss
[27]. This calculation yielded a requirement for 52 participants
in each group. Anticipating a dropout rate of 25%, we aimed
for a total sample size of 140. We also conducted a post hoc
power calculation. With an α of 0.05 and true baseline–end
correlation of 0.94, the power was 0.998 for the intention-to-
treat analysis and 0.969 for the per-protocol analysis.
Statistical analyses Normality of the data and homogeneity of
variances were tested using the Shapiro–Wilks test and
Levene’s test. Variables are expressed as numbers with per-
centages, means with SDs, medians with interquartile ranges
or means with 95% CI. Differences between the control and
intervention groups at baseline were tested using a χ2 test, an
independent samples t test or a Mann–Whitney U test, de-
pending on the normality of the data. Linear mixed modelling
was applied for analyses of between-group differences for the
2-year course for the primary and secondary outcomes. This
method efficiently handles data with missing and unbalanced
time points, and corrects for selective dropout when the miss-
ing values are dependent on variables present in the model
(missing at random) [28].
The models included three levels: group membership
(the highest level), participants (intermediate level) and
their repeated measures (lower level). The need for the
upper (group membership) level was determined with the
deviance statistic [29]. The fixed parts of the models
included the allocation arm; sex; linear, quadratic and
logarithmic time effects; and the interactions of allocation
and sex with time effects. Variance components matrices
were applied for the covariance structures. All analyses
were conducted according to the intention-to-treat and
per-protocol principles. Treatment was considered
per-protocol when participants attended at least nine
group-CBT sessions [13]. Per-protocol analyses were
restricted to the control group and compliant participants
in the intervention group. The difference in the number of
visits to the outpatient clinic during the study was analysed
using the Mann–Whitney U test. Results with p values of
<0.05 were considered statistically significant. Analyses
were carried out using SPSS version 21.0.
Results
Of the 296 individuals who were assessed from March 2010
until May 2013, 276 were eligible to participate in our study
and 206 gave written informed consent (Fig. 1). Compared
with individuals who participated in the study, those who de-
clined to participate were older (56.1 ± 10.3 vs 53.0 ±
10.8 years, p = 0.05) and more often male (61% vs 43%, p =
0.008). Themain reasons for refusal to participate were related
to work and a lack of time.
After the 8-week VLCD, 158 participants (77%; median
baseline BMI 36.3 [IQR 32.5–40.0] kg/m2) had lost ≥5% of
their body weight and were randomised to either the interven-
tion arm (n = 83) or the control group (n = 75). The difference
in numbers between the study arms resulted from the block
randomisation stratified by weight loss. The baseline charac-
teristics of participants who did and did not achieve ≥5%
weight loss are compared in the electronic supplementary ma-
terial (ESM) Table 1. The excluded individuals had signifi-
cantly higher baseline HbA1c levels, at 69.5 (59.3–86.3)
mmol/mol (8.5% [7.6–10.0%]) vs 60.0 (53.0–69.0)
mmol/mol (7.6% [7.0–8.5%]) (p = 0.001), and a higher anxi-
ety score (8.0 [4.0–11.0] vs 6.0 [3.0–9.0], p = 0.038) than the
included participants (all median [IQR]).
Baseline characteristics did not significantly differ between
the control and intervention groups (Table 1), except for the
EDE-Q score (p = 0.021). Eight participants in the control
group and 14 in the intervention group were lost to follow-
up at different time points during the study (p = 0.358)
(Fig. 1). Those participants were kept in the analyses as data
with missing time points.
The average number of usual care visits to the outpatient
diabetes clinic during the 2 years of follow-up was similar in
the intervention and control groups, at 12.0 (8.0–15.0) vs 13.0
(8.0–17.0) visits, respectively (p = 0.495). In addition, partic-
ipants in the intervention group attended a median of 9.0 (5.0–
14.0) group-CBT sessions. A total of 33 participants missed
more than eight sessions and were considered non-compliant.
Non-compliant participants attended amedian of 4.0 (0.0–7.0)
group-CBT sessions, while compliant participants attended
14.0 (11.0–15.3) sessions. Non-compliant participants were
significantly younger than compliant participants (49.0
[38.5–55.5] vs 56.0 [49.5–63.0] years; p = 0.004). The main
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reasons mentioned for non-compliance were health problems
and lack of time (work related). Overall, 20% of participants
in the intervention group and 12% in the control group report-
ed consulting an external psychologist (p = 0.187), with a me-
dian number of 3.5 (2.0–5.8) visits in the intervention group
and 4.0 (1.0–8.5) visits in the control group over 2 years (p =
0.978). Overall, 61% of participants in the intervention group
and 63% in the control group were referred to the diabetes
team’s dietitian as part of usual care (p = 0.218), with a median
of 2.0 (1.0–4.8) and 1.0 (0–3.0) visits during the 2 years of
follow-up, respectively (p = 0.082).
Weight change during the trial During the initial 8 weeks of
dieting, a mean weight loss of 10.0 (95% CI 9.1, 10.9) kg was
observed in the control group and 9.2 (95% CI 8.4, 10.0) kg in
the intervention group (p = 0.206 for between-group differ-
ence). At 2 years of follow-up, mean weight loss was 5.3
(95% CI 3.5, 7.2) kg and 5.2 (95% CI 3.4, 7.1) kg, respectively
(p = 0.951 for between-group difference). Overall, 38.6% of
participants still had weight loss of ≥5% after 2 years of fol-
low-up, including 17.7% whose weight loss remained ≥10%.
During the 2 year follow-up, 19.0% of participants managed to
fully maintain their lost weight. These percentages were similar
in both study arms (χ2 = 0.161, p = 0.688; χ2 = 0.307, p =
0.580; and χ2 = 0.077, p = 0.781, for participants who main-
tained ≥5%, ≥10% and complete weight loss, respectively).
Primary outcome We did not find a significant difference in
mean body weight between the intervention and control
groups at 2 years of follow-up (intention-to-treat analysis;
Table 2), at which point the mean between-group difference
was −1.2 (95% CI −7.7, 5.3) kg (p = 0.717). In the per-
protocol analysis the between-group difference was −3.8
(95% CI −11.5, 3.8) kg (p = 0.323). Mean weight regain dur-
ing follow-up was 4.7 (95% CI 3.0, 6.3) kg for the control
group and 4.0 (95% CI 2.3, 5.6) kg for the intervention group
at 2 years (46.7% and 43.0% of the lost weight at
randomisation, respectively; Table 2), with a between-group
difference of −0.7 (95% CI −3.1, 1.6) kg (p = 0.556) in the
intention-to-treat analysis and −0.6 (95% CI −3.3, 2.0) kg
(p = 0.635) in the per-protocol analysis. The deviance statistic
of the linear mixed model indicated that a three-level model
with a third upper ‘group’ level was not significantly better
than a two-level model with time and allocation (χ2(1) =
1.189; p = 0.28). ESM Table 2 shows the estimates of the
linear mixed model for weight during the study (intention-
to-treat). These results indicate that there was no allocation
effect and no allocation–time interaction. We also found no
interaction of sex with time and allocation (data not shown).
Secondary outcomes Change in weight from baseline to
2 years was not significantly different between the two groups,
at 0.1 (95% CI −2.5, 2.7) kg (p = 0.951) in the intention-to-
treat analysis (Fig. 2a) and −0.8 (95% CI −3.7, 2.2) kg (p =
0.613) in the per-protocol analysis (Fig. 2b).
None of the other secondary outcomes was significantly
different between the intervention and control groups at
2 years (Table 3). Furthermore, the change from baseline
was not different between the two groups for any of the sec-
ondary outcome variables (data not shown). None of the
Assessed for eligibility 
(n=296)
Excluded (n=90):
• Did not meet inclusion criteria 
(n=20)
• Refused to participate (n=70)
Started with 8 weeks of VLCD
(n=206)
Excluded:
• <5% weight loss (n=48)
Assigned to receive group-CBT (n=83)
• Compliant (n=50)
• Lost to follow-upa (n=2)
• Non-compliant (n=33)
• Lost to follow-upa (n=12)
Assigned to receive usual care (n=75) 
• Received usual care as assigned (n=75)
• Lost to follow-upa (n=8)
• Included in primary analysis
(intention-to-treat) (n=83)
• Included in per-protocol analysis (n=50)
• Included in primary analysis
(intention-to-treat) (n=75)
• Included in per-protocol analysis (n=75) 
Randomised (stratified block
randomisation)
(n=158)
Fig. 1 Study flow-chart.
aReasons for loss to follow-up:
three individuals became
pregnant, two moved to another
country, two moved to another
hospital, three underwent bariatric
surgery, two were diagnosed with
carcinoma, five no longer wanted
to participate and five failed to
respond to invitations for follow-
up visits
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primary or secondary outcomes differed between the two ther-
apists who conducted the group-CBT (data not shown). At
2 years of follow-up, both the intervention and control groups
had a significantly lower mean waist circumference, insulin
dose, depression score and fatigue score than at baseline
(p < 0.05). In addition, the EDE-Q subscale scores on weight
and shape concern significantly improved during the 2 years
of follow-up for both groups (p < 0.01).
Discussion
In this randomised controlled trial, group-CBT did not re-
duce the problem of weight regain following a successful
diet-induced weight reduction in overweight and obese
adults with type 2 diabetes. Moreover, the secondary out-
comes were not different between the intervention and con-
trol groups. For both groups, the average waist circumfer-
ence, insulin dose, depression score and fatigue score
remained significantly lower during follow-up after the
VLCD.
Weight regain usually occurs in the first year after weight
loss [4, 30–32]. In our study, participants in both groups
showed a gradual regain of weight of 43–47% of the initially
lost weight at 2 years of follow-up. In the Look AHEAD trial,
weight regain ranged from 40% to 60% during the 2 years
after achieving maximal weight loss, depending on the level
of weight loss achieved after 2 months of lifestyle intervention
and despite continued use of one daily meal replacement [33].
In post hoc analyses of the Look AHEAD trial, the subgroup
Table 1 Baseline participant
characteristics Characteristic Control (n = 75) Intervention (n = 83)
Age (years) 55.2 ± 9.3 52.3 ± 11.3
Age range (years) 32–73 28–74
Female 44 (58.7) 44 (53.0)
European descent 45 (60.0) 42 (50.6)
Low education 25 (33.3) 21 (25.3)
Employed 24 (32.0) 36 (43.4)
Employment (days/week) 0 (0–3.3) 0 (0–5)
Time from type 2 diabetes diagnosis (years) 10.0 (3.0–15.0) 8.0 (3.5–16.0)
Weight (kg) 106.7 ± 22.5 105.5 ± 19.3
BMI (kg/m2) 35.7 (32.9–40.9) 36.7 (31.7–39.4)
Waist circumference (cm) 120.4 ± 12.9 119.4 ± 14.2
Systolic blood pressure (mmHg) 145.0 ± 20.9 138.6 ± 18.6
Diastolic blood pressure (mmHg) 81.0 ± 10.5 80.2 ± 10.7
HbA1c (mmol/mol) 61.0 (53.8–68.3) 58.0 (51.5–72.0)
HbA1c (%) 7.7 (7.1–8.4) 7.5 (6.9–8.7)
Fasting glucose (mmol/l) 8.7 (6.9–10.5) 8.2 (6.8–10.8)
Total cholesterol (mmol/l) 4.4 (3.7–5.1) 4.5 (3.9–5.2)
LDL-cholesterol (mmol/l) 2.5 (2.0–3.0) 2.6 (2.2–3.1)
HDL-cholesterol (mmol/l) 1.2 (1.0–1.4) 1.1 (1.0 − 1.3)
Triacylglycerol (mmol/l) 1.7 (1.3–2.4) 2.0 (1.3–2.7)
Insulin users 49 (65.3) 52 (62.7)
Insulin dose among users (U/day) 100.1 ± 42.2 95.7 ± 54.9
Statin users 50 (66.7) 59 (71.1)
Clinical depression 12 (16.0)a 15 (18.1)a
Clinical anxiety disorder 12 (16.0)a 16 (19.3)a
Self-esteem (RSE score) 32.0 (28.0–35.0) 32.5 (27.0–35.0)
Quality of life (EQ-5D score) 0.78 (0.57–0.84) 0.81 (0.65–1.0)
Fatigue (CIS subscore 1) 37.0 (27.3–47.8) 36.5 (28.0–47.8)
Eating disorder (EDE-Q score) 1.9 ± 1.0 2.4 ± 1.2
Physical activity (SQUASH score) 2350 (1260–5355) 3495 (1440–5978)
Data are mean ± SD, median (interquartile range) or n (%)
a Per cent with HADS score >10
CIS, Checklist Individual Strength; EQ-5D, EuroQol five-dimension questionnaire; RSE, Rosenberg Self-Esteem
Scale; SQUASH, Short Questionnaire to Assess Health Enhancing Physical Activity
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of participants who had lost ≥10% of their initial body weight
at 1 year had greater odds of maintaining 10% weight loss at
8 years [4], and experienced a 20% decrease in the incidence
of cardiovascular disease comparedwith the control group [5].
This suggests that substantial sustained weight loss may be
beneficial for obese individuals with type 2 diabetes. In our
trial, only 18% of participants maintained a weight loss of
≥10% in both the intervention and control groups. Clearly,
group-CBT did not improve the magnitude of the sustained
weight loss. In the Look AHEAD trial [4], 17% of participants
in the control group and 27% of those in the intervention
group maintained a weight loss of ≥10% after 8 years of fol-
low-up. These results are more impressive than ours, poten-
tially because of a more intensive intervention or the increase
in physical activity during follow-up. Physical activity has
been shown to produce small but significant benefits to the
maintenance of weight loss [34]. In our study, physical activ-
ity did not differ between the groups during the 2 years of
follow-up.
VLCDs result in a substantial initial weight loss, and are
recommended by the American Diabetes Association for
weight loss in obese people with type 2 diabetes [35]. This
large initial weight loss creates a good starting situation to test
the effectiveness of strategies aiming at long-term weight
maintenance. Recent studies using other structured
programmes have found limited efficacy in weight mainte-
nance after initial VLCD-induced weight loss, where the
prolonged use of meal replacements and high-protein diets
holds most promise [36]. The data from these and our study
indicate that a multifaceted, long-term support programme is
needed to prevent weight regain after VLCD-induced weight
loss.
Observational studies specifically reporting on CBT in
combination with weight-loss dieting with or without increas-
ing physical activity have shown favourable effects on long-
term weight loss in obese individuals with type 2 diabetes [11,
12]. However, since group-CBT was part of an intensive,
combined intervention including diet and exercise, no conclu-
sions can be drawn on the effectiveness of group-CBT itself.
Clearly, our randomised controlled trial does not support a
beneficial effect of group-CBT on top of usual care.
In obese adults without type 2 diabetes, positive effects of
group-CBT on weight loss and weight-loss maintenance have
been described, and this treatment option has been incorporat-
ed into international obesity guidelines [6, 7, 37, 38]. In addi-
tion to methodological considerations, our intervention differs
from that investigated in these previous studies by having a
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Fig. 2 Estimates of weight from baseline to 2 years for the group-CBT
and control groups. (a) Intention-to-treat and (b) per-protocol analysis.
Solid line, group-CBT; dashed line, control group. p = 0.951 (intention-
to-treat) and p = 0.613 (per protocol) for between-group difference in
course of weight from baseline to 2 years of follow-up, analysed using
a mixed-modelling procedure
Table 2 Weight and weight re-
gain over 2 years of follow-up Outcome Control group Intervention group Between-group difference
Weight (kg)
−8 weeks (baseline) 106.8 (102.3, 111.2) 105.5 (101.3, 109.7) −1.3 (−7.4, 4.9)
0 weeks (randomisation) 96.8 (92.4, 101.2) 96.3 (92.1, 100.5) −0.5 (−6.6, 5.6)
12 weeks 95.7 (91.3, 100.1) 95.2 (91.0, 99.4) −0.4 (−6.5, 5.7)
52 weeks 98.5 (94.0, 103.0) 97.7 (93.4, 102.0) −0.8 (−7.0, 5.4)
78 weeks 100.6 (96.1, 105.2) 99.6 (95.2, 103.9) −1.0 (−7.3, 5.3)
104 weeks 101.4 (96.7, 106.1) 100.2 (95.8, 104.7) −1.2 (−7.7, 5.3)
Weight regain from randomisation (kg)
52 weeks 1.7 (0.6, 2.8) 1.4 (0.4, 2.5) −0.3 (−1.8, 1.2)
78 weeks 3.8 (2.5, 5.2) 3.3 (2.0, 4.6) −0.6 (−2.5, 1.4)
104 weeks 4.7 (3.0, 6.3) 4.0 (2.3, 5.6) −0.7 (−3.1, 1.6)
Data are means (95% CI)
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substantially longer follow-up and restricting participation to
individuals with diabetes. Our intervention was based on the
protocol of Werrij et al [7]. They found that in obese non-
diabetic individuals, group-CBT was superior to increasing
physical activity in maintaining diet-induced weight loss.
Notably, both the control and intervention groups did equally
well in reducing EDE-Q subscale scores, which indicates a
change in cognitions. EDE-Q subscale scores improved sim-
ilarly in both our study groups, but this apparent change in
cognitions did not result in improvedweight-loss maintenance
in the intervention group. Our results are in concordance with
those of a randomised controlled trial with a follow-up period
of 3 years, in which group-CBT did not improve weight-loss
maintenance in obese individuals without type 2 diabetes de-
spite improvements in cognition scores [39]. Obviously, the
precise mechanisms through which CBT produces its effects
are still unknown, making it unclear which measure of change
in cognitions is relevant.
A recent meta-analysis showed that (group)-CBT reduces
depressive symptoms in people with diabetes [40]. We found
no effect of group-CBT on the HADS depression scale.
However, our group-CBT was specifically designed for and
aimed at maintenance of body weight loss, and not at allevi-
ating depression.
It could be argued that individual CBT is more effective
than group-CBT. In obesity research, however, group-CBT
has been shown to be equally [8] or even more effective [9]
than individual CBT in achieving weight loss and reducing
attrition. Similarly, anxiety and obsessive compulsive disor-
ders respond at least as well to group-CBT as to individual
therapy [41, 42].
The rate of non-compliance with the group-CBT interven-
tion in our study was 40%, which is similar to the 35–50%
non-compliance reported in other CBT studies [43]. Non-
compliance may have diminished the effect of the group-
CBT. However, analyses restricted to the compliant group
did not show an effect of group-CBT on weight at 2 years,
nor at any intermediate time point. Notably, post hoc power
calculations showed that we included a sufficient number of
participants for the intention-to-treat as well as for the per-
protocol analysis to enable relatively small differences to be
detected (Table 2 of reference [13]).
The lack of an effect of group-CBT could be attributed to
the psychological treatment received outside the study. The
self-reported psychological consultation outside the study
was similar for both groups. Alternatively, the usual care given
to all our participants could have diminished the contrast be-
tween both study arms. Over the years, usual care has incor-
porated more and more effective elements of therapy. It is
quite possible that our usual care already contains specific or
non-specific treatment factors that makes it effective for
weight-loss maintenance, thereby diminishing the effect of
additional group-CBT. Nonetheless, we still observed a large
window for improvements in maintaining weight. Whatever
Table 3 Differences in secondary
outcome variables after 2 years of
follow-up between the interven-
tion and control groups
Outcome variablesa Control group Intervention group Between-group
difference
Waist circumference (cm) 116.0 (112.7, 119.2) 115.0 (111.9, 118.1) −1.0 (−5.4, 3.5)
Systolic blood pressure (mmHg) 140.0 (135.4, 144.7) 139.2 (134.8, 143.7) −0.8 (−7.3, 5.6)
HbA1c (mmol/mol) 64.9 (60.6, 69.1) 64.0 (59.8, 68.1) −0.9 (−6.8, 5.0)
HbA1c (%) 8.1 (7.7, 8.5) 8.0 (7.6, 8.4) −0.1 (−0.6, 0.5)
Insulin dose (U/day) 43.5 (26.9, 60.1) 40.4 (24.3, 56.6) −3.1 (−26.3, 20.2)
Total cholesterol (mmol/l) 4.20 (3.90, 4.50) 4.48 (4.19, 4.77) 0.29 (−0.13, 0.70)
LDL-cholesterol (mmol/l) 2.34 (2.10, 2.58) 2.65 (2.42, 2.88) 0.31 (−0.03, 0.64)
HDL-cholesterol (mmol/l) 1.24 (1.16, 1.32) 1.22 (1.14, 1.30) −0.02 (−0.13, 0.10)
Triacylglycerol (mmol/l) 2.08 (1.50, 2.66) 2.29 (1.73, 2.84) 0.21 (−0.60, 1.01)
Depression (HADS score) 5.3 (4.2, 6.3) 5.5 (4.5, 6.6) 0.3 (−1.2, 1.8)
Anxiety (HADS score) 5.3 (4.1, 6.4) 6.1 (4.9, 7.2) 0.8 (−0.8, 2.4)
Self-esteem (RSE score) 31.1 (29.1, 33.1) 29.9 (27.9, 31.9) −1.2 (−4.0, 1.7)
Quality of life (EQ-5D score) 0.69 (0.62, 0.76) 0.69 (0.63, 0.76) 0.01 (−0.09, 0.10)
Fatigue (CIS score) 31.2 (27.9, 34.5) 33.4 (30.2, 36.7) 2.2 (−2.4, 6.9)
Eating disorders (EDE-Q score) 1.70 (1.39, 2.01) 2.11 (1.80, 2.41) 0.41 (−0.02, 0.84)
Physical activity (SQUASH
score)
4176 (2160, 6191) 5453 (3427, 7480) 1278 (−1580, 4136)
a Estimates after 2 years of follow-up and between-group difference (95% CI), analysed via a linear mixed-model
procedure according to the intention-to-treat principle
CIS, Checklist Individual Strength; EQ-5D, EuroQol five-dimension questionnaire; RSE, Rosenberg Self-Esteem
Scale; SQUASH, Short Questionnaire to Assess Health Enhancing Physical Activity
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explains the lack of effect of group-CBT in our study, it is
unlikely that our group-CBT can contribute to weight mainte-
nance in treated obese individuals with type 2 diabetes.
Strengths of our study include the randomised con-
trolled design and the relatively long follow-up period.
Participants were referred to a single tertiary centre, and
therefore our findings may not be generalisable to the
entire population of overweight and obese people with
type 2 diabetes. Obviously, our findings are exclusively
applicable to individuals who are motivated and able to
lose ≥5% of their body weight by dieting. Finally, our trial
had a pragmatic design, not compensating for the in-
creased attention received by the intervention group.
Despite this increased attention, there were no differences
in outcomes between the two arms, thus strengthening our
conclusions.
From this high-quality randomised controlled trial, we
conclude that despite increased treatment contact, group-
CBT is not more effective for maintaining long-term
weight loss than usual care alone in overweight and obese
individuals with type 2 diabetes who were initially able to
lose a clinically relevant amount of body weight on a
VLCD. Future research should focus on identifying other
CBT approaches in combination with other therapies to
improve the long-term effectiveness of weight-loss
dieting.
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